Clear Cell Renal Cell Carcinoma
Key Points
Key Points
- Kidney cancer will be diagnosed in 79,000 U.S. patients in 2022 and will account for 13,920 deaths.
- Opportunities for extended survival and even durable disease control in the metastatic setting have recently appeared as novel classes of therapeutics, reshaping the trajectory of this cancer.
- This rapid evolution has paved the way for this first set of comprehensive guidelines for treating metastatic clear cell renal cell carcinoma (ccRCC).
Diagnosis
...Di...
...mendation 1.1The diagnosis of metastatic clear c...
...endation 1.2Radiographic diagnosis of metast...
Treatment
...Tr...
...2.1Select patients (see Practical Information)...
Recommendation 3.1Select patients...
...1. First-Line Treatment...
...mendation 3.2All patients with metasta...
....3Patients with favorable risk dis...
...dation 3.4Select patients with metastatic cl...
...dation 3.5The use of high dose interleukin-2 (HD...
...n 4.1Nivolumab or cabozantinib should be o...
...mmendation 4.2Patients progressing on co...
...ndation 4.3Patients who progress afte...
...commendation 4.4For patients on immunotherapy...
...mendation 5.1For patients with low vo...
...dation 5.2For patients undergoing co...
...tion 6.1.1Patients with symptomatic bon...
...tion 6.1.2Patients with bone metastas...
Recommendation 6.1.3No recommendation regardi...
...igure 2. Second-Line or Greater Treatmen...
...etastases-Directed Treatment...
Recommendation 6.2.1Patients with brain met...
...endation 6.2.2No recommendation regardi...
....3Patients with metastatic clear cell...
...4. Special Patient Subtypes...
...SCO believes that cancer clinical...